On Open-Label Study in Participants With Systemic Lupus Erythematosus

• Status: Terminated
• Trial end date: 2015-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this SLE study is to evaluate the long-term safety and efficacy of LY2127399 in eligible SLE participants who have completed the core studies (NCT01196091) (NCT01205438).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Antibodies, Monoclonal

Criteria

Inclusion Criteria:

• Have completed 52 weeks of treatment in core studies (NCT01196091) (NCT01205438)

• Given written informed consent

• Test negative for pregnancy at the time of enrollment

• Agree to use a reliable method of birth control

Exclusion Criteria:

• Unwilling to comply with study procedures

• Any condition that renders the participants unable to understand the nature and scope and possible consequences of the study

• Any condition that in the opinion of the investigator poses an unacceptable risk to the participants if study drug would be administered